Gregory Day, MD
Neurology · Jacksonville, FLNPI 1962880757
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,988 of the $6,168 with a category attached, or 64.7%. Eli Lilly accounts for 86.8% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $4,168 and has fallen 96.8% since, to $132 in 2025.
Across 13 payments — averaging $474.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$5K
- Amgen$388
- UCB, Inc.$296
- TG Therapeutics, Inc.$132
Across 6 payments — averaging $28,736 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$172K
What the payments were for
- Speaking & faculty fees$3,98865%
- Travel & lodging$1,26921%
- Food & beverage$91115%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 5 | $5,352 |
| Amgen(2 entities) | 4 | $388 |
| UCB, Inc. | 3 | $296 |
| TG Therapeutics, Inc. | 1 | $132 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,168 in reported general payments places this provider in the 65th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 25 | $5,204 |
| Donepezil Hcl | 134 | $2,035 |
| Mirtazapine | 21 | $1,225 |
| Memantine Hcl | 16 | $871 |
| Quetiapine Fumarate | 14 | $398 |
| Escitalopram Oxalate | 13 | $143 |
Paid to pharmacies, not to this prescriber.
Other neurology in Jacksonville
- Steven ToenjesJacksonville$695K
- Zhigao HuangJacksonville$613K
- Kalina SandersJacksonville$544K
- Syed AsadJacksonville$302K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.